News

November 16, 2026

In Conversation with UBS: Tenvie’s Clinical Programs, Development Plans and Pipeline Optionality

We appreciated the opportunity to join UBS for a conversation with Tenvie Co-Founder, CEO, and President Tony Estrada about our clinical-stage pipeline and upcoming milestones.

Tony discussed Tenvie’s two fully CNS-penetrant NLRP3 inhibitors, TNV262 and TNV313, and TNV108, a peripherally restricted SARM1 inhibitor. The conversation covered TNV262’s planned Phase II studies in obesity and MS, as well as the potential of our broader pipeline across neurologic and peripheral diseases.

Watch the replay and read UBS’s takeaways here & below.

1. TNV262 is a Phase II-ready, fully CNS-penetrant NLRP3 inhibitor with Phase IIs planned to initiate next year in both obesity and MS. Recall the thesis is that hypothalamic neuroinflammation / microglial activation disrupts satiety signaling, requiring sufficient NLRP3 inhibition in the brain to drive WL. Tenvie believes they are uniquely positioned to test the NLRP3 obesity thesis given high CNS exposure: TNV262 achieves CSF:plasma Kpu >1 vs. ~0.5-0.7 for competitors including BIOA, VTYX/LLY and NodThera and avoids P-gp-mediated efflux, per mgmt. Thus mgmt believes TNV262 can at relatively low doses maintain >IC90 trough exposure in the brain, whereas competitors would require much higher plasma exposure to achieve comparable CNS inhibition.

Tenvie plans to start a 12-week Phase II obesity study in 2027 evaluating TNV262 monotherapy and in combination with semaglutide, with data expected Q4/27. The study will assess WL as well as peripheral inflammatory biomarkers seen with other NLRP3 inhibitors and additional biomarkers including IL-18 and other obesity/adipose-related markers. The positioning is less about competing with GLP-1s on absolute WL and more about (1) combination therapy that could enable lower GLP-1 dosing and thus better tolerability while maintaining WL and (2) TNV262 monotherapy as maintenance after GLP-1-induced WL. In the OLE, both arms will converge onto monotherapy TNV262 to test the maintenance hypothesis.

2. Regarding the recent NVO ZEUS data, mgmt believes the negative IL-6 result does not invalidate the NLRP3 thesis and instead pot'l show that IL-6 may be more correlative than causative. In contrast, IL-1B inhibition with canakinumab demonstrated a stat sig MACE benefit in CANTOS (HR 0.85)… NLRP3 sits further upstream, impacting both IL-1B and IL-18. Mgmt therefore views NLRP3 as potentially more relevant to CV outcomes than selective IL-6 inhibition. Importantly, NVO continues to advance its NLRP3 portfolio acquired from Ventus and sees NLRP3 as pot'l more promising than IL6 post ZEUS, while LLY acquired VTYX for its NLRP3 portfolio for CV and Roche is also developing NLRP3 inhibitors across both CV and neuro indications.

3. In MS, Tenvie expects to start a Phase II trial of TNV262 next year that will run in parallel with the obesity Phase II, with initial GAD lesion data expected Q1/28 followed by a progression-focused readout. Mgmt believes NLRP3 inhibition could address compartmentalized neuroinflammation downstream of BTK and has seen preclinical efficacy similar to BTK inhibition without the associated tox.The goal is to demonstrate efficacy competitive with traditional MS agents / BTKis while maintaining a cleaner safety and tolerability profile.

4. Tenvie also has optionality via TNV313, a second fully CNS-penetrant NLRP3 inhibitor currently in Phase I, with initial HV safety and PK data expected H1/27. Having two CNS-penetrant NLRP3 assets provides strategic optionality across cardiometabolic and neurologic indications, including the ability to separate indications with different development timelines and pricing dynamics. And more under-the-radar is TNV108, a peripherally restricted allosteric SARM1 inhibitor being developed for peripheral neuropathies starting with DPN. Unlike Nav1.7/1.8 approaches focused primarily on symptomatic pain relief, the SARM1 thesis is potentially disease modifying by preventing axonal degeneration upstream. Initial Phase I safety / PK data are expected H2/26.

Related